CN Patent

CN115340523B — 一种具有alk抑制活性的化合物及其制备方法和用途

Assigned to Shengshi Taike Biopharmaceutical Technology Suzhou Co ltd · Expires 2023-12-15 · 2y expired

What this patent protects

本发明涉及药物化学相关的技术领域，具体涉及一种具有ALK抑制活性的化合物及其制备方法和用途。本发明提供的具有ALK抑制活性的化合物，是一种用于治疗对抑制ALK激酶有响应的疾病的ALK抑制剂，可用于治疗ALK呈阳性的相关疾病，例如肿瘤和癌症，具有广阔的应用前景。

USPTO Abstract

本发明涉及药物化学相关的技术领域，具体涉及一种具有ALK抑制活性的化合物及其制备方法和用途。本发明提供的具有ALK抑制活性的化合物，是一种用于治疗对抑制ALK激酶有响应的疾病的ALK抑制剂，可用于治疗ALK呈阳性的相关疾病，例如肿瘤和癌症，具有广阔的应用前景。

Drugs covered by this patent

alectinib-hydrochloride (ALECTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN115340523B
Jurisdiction: CN
Classification: —
Expires: 2023-12-15
Drug substance claim: No
Drug product claim: No
Assignee: Shengshi Taike Biopharmaceutical Technology Suzhou Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.